Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;5(7):977-92.
doi: 10.2217/fon.09.57.

Clinical states model for biomarkers in bladder cancer

Affiliations
Review

Clinical states model for biomarkers in bladder cancer

Andrea B Apolo et al. Future Oncol. 2009 Sep.

Abstract

Bladder cancer is a significant healthcare problem in the USA, with a high recurrence rate, the need for expensive continuous surveillance and limited treatment options for patients with advanced disease. Research has contributed to an understanding of the molecular pathways involved in the development and progression of bladder cancer, and that understanding has led to the discovery of potentially diagnostic, predictive and prognostic biomarkers. In this review, a clinical states model of bladder cancer is introduced and integrated into a paradigm for biomarker development. Biomarkers are systematically incorporated with predefined end points to aid in clinical management.

PubMed Disclaimer

Figures

Figure
Figure. A dynamic clinical states model in bladder cancer (Adapted from Scher et al[8])

Similar articles

Cited by

References

    1. Whelan P. Bladder Cancer--Contemporary Dilemmas in Its Management. European Urology. 2008;53(1):24–26. - PubMed
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics. 2003;21(18):1315–1330. - PubMed
    1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675. - PubMed
    1. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608. - PubMed
    1. Bishop J, Weinberg RA. Molecular Oncology. Scientific American, Inc; New York: 1996.

Substances